Compare Crispr Therapeutics AG (CRSP) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Russell 2000 ETF — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while iShares Russell 2000 ETF trades at $294.39. The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | IWM | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | — |
52-Week High | $76.78 | $300.45 |
52-Week Low | $44.34 | $214.95 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
IWM trades at $293.44, down 0.85% on the day amid a bearish technical signal. The ETF shows mixed momentum with moving averages bullish but oscillators neutral, while recent news highlights small-cap outperformance versus large caps year-to-date. Support levels cluster around $289-292 with resistance at $295-298. The Russell 2000 has gained 22.1% YTD according to The Motley Fool (2026-07-02), though some analysts question sustainability amid Fed policy uncertainty.
Outlook remains bifurcated: strong small-cap performance offers growth potential in economic expansion, but higher volatility and interest rate sensitivity pose risks. The ETF's 0.19% expense ratio and diversification across nearly 2,000 stocks provide structural benefits, though valuation concerns persist as passive flows increase exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
